A randomized controlled trial studying the effectiveness of group medical appointments on self-efficacy and adherence in sickle cell disease (TEAM study): study protocol

Marlous J. Madderom,
Jessica Heijdra,
Elisabeth M. W. J. Utens,
Suzanne Polinder,
Anita W. Rijneveld and
Marjon H. CnossenEmail author

BMC HematologyBMC series – open, inclusive and trusted201616:21

DOI: 10.1186/s12878-016-0058-4

Received: 28 January 2015

Accepted: 16 June 2016

Published: 4 August 2016

Open Peer Review reports

Abstract

Background

Sickle cell disease (SCD) is endemic in non-Western countries. Due to migration, the prevalence of SCD in the Netherlands has increased. Adherence to medical treatment is recognized as a major problem area. Therefore, new effective interventions to increase adherence are urgently needed.

Methods/design

The TEAM study is an ongoing randomized controlled trial (RCT) to compare protocolized individual medical appointments (IMA’s; care-as-usual) with protocolized group medical appointments (GMA’s; novel intervention) in pediatric (n = 40) and adult (n = 60) patients. The study aims to assess the effectiveness of GMA’s (over a three year period) on patients’ self-efficacy, adherence, quality of life, morbidity, hospital admissions and satisfaction with the treating professional; as well as to test the cost-effectiveness of GMA’s. In both the IMA and GMA groups structured assessments will be performed at baseline (start of the study), after 1.5 and after 3 years.

Discussion

This is the first RCT to investigate the effectiveness of GMA’s on self-efficacy and adherence in pediatric and adult patients with SCD, including a cost-effectiveness analysis.